Cetera Investment Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Cetera Investment Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,090	Closed	-$644K	–	4202
2025 Q1	$644K	Sell	10,090 -1,084	-10%	-$114K	﹤0.01%	2635
2024 Q4	$1.36M	Buy	11,174 +463	+4%	+$56.7K	﹤0.01%	1941
2024 Q3	$1.34M	Sell	10,711 -2,302	-18%	-$318K	﹤0.01%	1904
2024 Q2	$2.06M	Buy	13,013 +1,022	+9%	+$131K	﹤0.01%	1554
2024 Q1	$1.55M	Buy	11,991 +2,590	+28%	+$317K	﹤0.01%	1744
2023 Q4	$907K	Buy	+9,401	New	+$902K	0.01%	1153
2021 Q3	–	Sell	-3,561	Closed	-$277K	–	1868
2021 Q2	$277K	Buy	+3,561	New	+$270K	﹤0.01%	1469
2021 Q1	–	Sell	-2,040	Closed	-$348K	–	1699
2020 Q4	$348K	Buy	+2,040	New	+$302K	0.01%	1156

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Cetera Investment Advisers's SRPT Position: Q2 2025 in Review

Cetera Investment Advisers sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 10,090 shares — an estimated $644K sold.

Cetera Investment Advisers first reported a position in SRPT in Q4 2020 and held it in 8 quarters. The position peaked at $2.06M in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Cetera Investment Advisers reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Cetera Investment Advisers sold 10,090 Sarepta Therapeutics shares in Q2 2025, an estimated $644K.
Cetera Investment Advisers first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 8 quarters.
Cetera Investment Advisers's Sarepta Therapeutics position peaked at $2.06M in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Cetera Investment Advisers's 13F filing for Q2 2025, filed 8 Aug 2025.